Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders

@article{Balakumar2012SubmaximalPA,
  title={Submaximal PPAR$\gamma$ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders},
  author={Pitchai Balakumar and Sonam Kathuria},
  journal={British Journal of Pharmacology},
  year={2012},
  volume={166}
}
PPARγ activation plays an important role in glucose metabolism by enhancing insulin sensitization. PPARγ is a primary target for thiazolidinedione‐structured insulin sensitizers like pioglitazone and rosiglitazone employed for the treatment of type 2 diabetes mellitus. Additionally, PPARγ activation inhibits adhesion cascades and detrimental vascular inflammatory events. Importantly, activation of PPARγ plays a distinctive role in regulating the physiology and expression of endothelial nitric… 
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
TLDR
The most meaningful and up-to-date in vitro and in vivo studies of the regulation of NO production performed by different PPAR agonists are reported, providing insights into the molecular mechanisms of PPAR-mediated eNOS activation.
Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications
TLDR
The aim of this article was to summarize the current knowledge related to signaling mechanisms of the pioglitazone-induced improvement or reversal of ED, as well as the relevant clinical studies and possible therapeutic implications connected toPioglitrazone-related action on the endothelium.
A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia
TLDR
A recently introduced PPARα/γ dual agonist, saroglitazar is an emerging therapeutic agent of glitazar class approved in India for the management of diabetic dyslipidemia and its treatment has been reported to be generally safe and well tolerated.
The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
  • W. Ahsan
  • Biology
    Current pharmaceutical design
  • 2019
TLDR
The role of PPARs in the management of T2D is focused on; recently reported TZD derivatives which acted as agonists of PPar- γ and its subtypes and are potentially useful in the new drug discovery for the disease.
Gr upSM Functioning of the PPAR Gamma and its Effect on Cardiovascular and Metabolic Diseases
TLDR
Peroxisome proliferator-activated receptors (PPAR) belong to nuclear super family of ligandactivated transcriptional factors, which regulates a number of homeostatic functions, such as glucose and lipid metabolism.
Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones
TLDR
The present review summarizes the current advances in the biochemical and physiological aspects in the treatment of type 2 diabetes mellitus with thiazolidinediones (TZDs), which are able to lower blood glucose levels and circulating triglycerides by binding to the nuclear peroxisome proliferator-activated receptor gamma (PPARγ) as full agonists.
Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities
TLDR
Interestingly, the co-administration of peroxisome proliferator-activated receptor γ (PPARγ) antagonist, GW9662 submaximally, significantly prevented rosuvastatin-induced improvement in vascular endothelial integrity, endothelium-dependent relaxation, and nitrite/nitrate concentration in rats administered nicotine.
Pioglitazone Improves Endothelial Function in Patients with Paroxysmal Atrial Fibrillation and Type 2 Diabetes Mellitus Following Catheter Ablation
TLDR
After 12 months of followingup, FMD improved significantly in the pioglitazone group compared to the control group as well as baseline, and piog litazone treatment also led to higher circulating EPCs number and serum eNOS level.
...
...

References

SHOWING 1-10 OF 116 REFERENCES
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?
TLDR
Future prospective clinical trials designed for the specific purpose of establishing the cardiovascular benefit or risk of rosiglitazone would be the best way to resolve the uncertainties regarding the safety of ro'siglitrazone in patients with heart disease.
PPAR dual agonists: are they opening Pandora's Box?
Peroxisome Proliferator-Activated Receptor-γ Agonists for Management and Prevention of Vascular Disease in Patients with and without Diabetes Mellitus
TLDR
The current understanding of the role of PPAR-γ agonists in atherogenesis is summarized and their potential role in the treatment of coronary artery disease in patients with type 2 diabetes mellitus and in nondiabetic patients is discussed.
Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice.
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
TLDR
The current understanding of the role of PPAR-gamma agonists in atherogenesis is summarized and their potential role in the treatment of coronary artery disease in patients with type 2 diabetes mellitus and in nondiabetic patients is discussed.
Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
TLDR
Weighing the potential benefit and harm of PPAR-γ activation and exploring the functional mechanisms may provide a balanced view on the clinical use of these compounds and new approaches to the future therapeutics of vascular disorders associated with diabetes.
Thiazolidinediones: effects on insulin resistance and the cardiovascular system
TLDR
Clinically, TZDs have been shown to reduce measures of atherosclerosis such as carotid intima‐media thickness (CIMT), and the safety of rosiglitazone in this respect has recently been called into question.
Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
TLDR
Beyond partial improvement in insulin sensitivity, rosuvastatin normalized BP homeostasis in obese dyslipidaemic mice independently of changes in body weight or plasma cholesterol, suggesting upregulation of PPARgamma and SOD1 in the endothelium may be involved as a unique vasculoprotective effect of statin treatment.
Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Agonist Improves Coronary Artery Endothelial Function in Diabetic Patients with Coronary Artery Disease
TLDR
Results suggest that, in addition to its beneficial metabolic effects, rosiglitazone, via its anti-inflammatory effects, may improve endothelial function of the coronary arteries in patients with diabetes and CAD.
...
...